TITLE

ORQIS MEDICAL BEGINS EUROPEAN CLINICAL TRIAL FOR CRS SYSTEM

PUB. DATE
January 2003
SOURCE
Worldwide Biotech;Jan2003, Vol. 15 Issue 1, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the medical devices being developed by Orqis Medical for the treatment of Class III and IV congestive heart failure.
ACCESSION #
8775078

 

Related Articles

  • Orqis Lands $23M; Total Raised Now $60M. Reed, Vita // Orange County Business Journal;6/27/2005, Vol. 28 Issue 26, p3 

    Reports on the amount raised by Orqis Medical Corp. in a fourth round of venture capital funding in Orange County, California. Specialization of the company in developing devices to fight congestive heart failure; Participation of Johnson & Johnson Development Corp. in the deal; Plans of Orqis...

  • Bayer PC bolsters new heart-pump system. Renstrom, Roger // Plastics News;2/26/2007, Vol. 18 Issue 52, p13 

    The article reports on the effective use of polycarbonate by Orqis Medical Corp. and Levitronix in a system proposed to treat patients with chronic congestive heart failure. The system supplements the heart in pumping blood to the body. Orqis sought guidance from Bayer MaterialScience LLC of...

  • Older heart drug cuts death rate by 30%. Hensley, Scott // Modern Healthcare;07/26/99, Vol. 29 Issue 30, p24 

    Discusses the re-discovery of spironolactone, a drug that blocks the action of a hormone called aldosterone. Implications of the discovery of the drug on hospitals and health systems; Number of people hospitalized with congestive heart failure.

  • Coronary Stent Implantation in Patients with a Single Coronary Artery. Sasao, Hisataka; Hasegawa, Tohru; Endo, Akita; Fujiwara, Tadashi; Kikuchi, Yuka; Oimatsu, Hiroshi; Takada, Takehito // Angiology;Jan2003, Vol. 54 Issue 1, p131 

    An isolated single coronary artery is a rare congenital anomaly and a cause of cardiac ischemia, congestive heart failure, and sudden cardiac death. Reported here are 3 cases of single coronary artery with acute myocardial infarction in which coronary stenting was performed. Also reported are...

  • Therapeutic options for congestive heart failure. Ross, Brendan S.; King, Jeffery M.; Fischer, Richard G. // Drug Topics;2/16/98, Vol. 124 Issue 4, p102 

    Presents information on congestive heart failure (CHF) with reference to its therapeutic options in the United States. Estimation of the amount of Americans who are afflicted with CHF; What have been associated with the increase prevalence and incidence of heart failure; Details on the diagnosis...

  • New Test for Congestive Heart Failure.  // Medical Update;Jul2002, Vol. 28 Issue 1, p5 

    Provides information on a 15-minute test which detects the presence of congestive heart failure.

  • Medication Safety and Reliability.  // Formulary;Jul2003, Vol. 38 Issue 7, p411 

    Reports on the risk of myocardial damage associated with the prescription and use of cytotoxic agent, doxorubicin, in the field of oncology. Major risk factor for doxorubicin-related congestive heart failure; Results of lung and breast cancer trials; Relation of patient symptoms to doxorubicin.

  • Quality watch. Montague, Jim; Pitman, Hilarie // H&HN: Hospitals & Health Networks;2/5/96, Vol. 70 Issue 3, p14 

    Reports on the benefits of extensive patient education and follow-up care to treat congestive heart failure. Comparison of costs; Implications.

  • ...-blockade saves lives in congestive heart failure. Pinkowish, Mary Desmond // Patient Care;10/15/1997, Vol. 31 Issue 16, p171 

    Reports that according to a meta-analysis, ...-blockade may offer significant mortality reductions to patients with chronic congestive heart failure (CHF). Description of experiments conducted in study; Odds of death; Speculations on the influence of ...-blockers delay on CHF.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics